Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
A phase 1/2 trial of Pomalidomide, Dexamethasone, Azacitidine in hodgkin lymphoma and non-hodgkin lymphoma, run by CellCentric Ltd., now recruiting.
Overview
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies is a phase 1/2 interventional study registered as NCT04068597 by CellCentric Ltd., with 250 participants planned, started 2019-08-09 and due to reach its primary completion in 2027-03-31. Interventions recorded: CCS1477, Pomalidomide, Dexamethasone, Azacitidine, Venetoclax. Conditions listed: Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex)
Shares Pomalidomide, Dexamethasone, Venetoclax, Multiple myeloma.
- TrialAll Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myelo
Shares Pomalidomide, Bortezomib, Dexamethasone, Multiple myeloma.
- TrialA Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Re
Shares Pomalidomide, Bortezomib, Dexamethasone, Multiple myeloma.
- TrialA Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
Shares Pomalidomide, Bortezomib, Dexamethasone, Multiple myeloma.
- TrialA Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractor
Shares Bortezomib, Dexamethasone, Venetoclax, Multiple myeloma.
- TrialA Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With
Shares Pomalidomide, Bortezomib, Dexamethasone, Multiple myeloma.
- TrialA Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Mult
Shares Pomalidomide, Bortezomib, Dexamethasone, Multiple myeloma.
- TrialPhase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
Shares Pomalidomide, Bortezomib, Dexamethasone, Multiple myeloma.